Psychopharmacology (2011) 214:911–921 Greene R (2001) Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippo- campus 11:569–577 Guscott MR, Clarke HF, Murray F, Grimwood S, Bristow LJ, Hutson PH (2003) The effect of (±)-CP-101, 606, an NMDA receptor NR2B subunit selective antagonist, in the Morris water maze. Eur J Pharmacol 476:193–199 Higgins GA, Ballard TM, Huwyler J, Kemp JA, Gill R (2003) Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharma- cology 44:324–341 Higgins GA, Ballard TM, Enderlin M, Haman M, Kemp JA (2005) Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. Psychopharmacol Berl 179:85–98 Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27:11496–11500 Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308 Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacol- ogy 20:201–225 Kotermanski SE, Johnson JW (2009) Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J Neuro- sci 29:2774–2779 Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS (1994) Subanes- thetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuro- endocrine responses. Arch Gen Psychiatry 51:199–214 Krystal JH, Bennett A, Abisaab D, Belger A, Karper LP, Dsouza DC, Lipschitz D, Abidargham A, Charney DS (2000) Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 47:137–143 Laube B, Kuhse J, Betz H (1998) Evidence for a tetrameric structure of recombinant NMDA receptors. J Neurosci 18:2954–2961 Laurent V, Podhorna J (2004) Subchronic phencyclidine treatment impairs performance of C57BL/6 mice in the attentional set- shifting task. Behav Pharmacol 15:141–148 Levi Y, Kofman O, Schwebel M, Shaldubina A (2008) Discrimination and avoidance learning in adult mice following developmental exposure to diisopropylfluorophosphate. Pharmacol Biochem Behav 88:438–445 Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31:234–242 Loftis JM, Janowsky A (2003) The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther 97:55–85 Luby ED (1959) Study of a new schizophrenomimetic drug—Sernyl. A M A Arch Neurol Psychiatry 81:363–369 921 Monaghan DT, Larsen H (1997) NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology. J Pharmacol Exp Ther 280:614–620 Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529–540 Mutel V, Buchy D, Klingelschmidt A, Messer J, Bleuel Z, Kemp JA, Richards JG (1998) In vitro binding properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J Neurochem 70:2147–2155 Nikiforuk A, Golembiowska K, Popik P (2010) Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur Neuropsychopharmacol 20:37–48 Olney JW, Farber NB (1995) NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13:335–345 Ozawa S, Kamiya H, Tsuzuki K (1998) Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 54:581–618 Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, Robbins TW (1999) Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37:251–270 Papaleo F, Crawley JN, Song J, Lipska BK, Pickel J, Weinberger DR, Chen J (2008) Genetic dissection of the role of catechol-O- methyltransferase in cognition and stress reactivity in mice. J Neurosci 28:8709–8723 Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J (2008) Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT(6) receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33:2657–2666 Schorge S, Colquhoun D (2003) Studies of NMDA receptor function and stoichiometry with truncated and tandem subunits. J Neuro- sci 23:1151–1158 Skolnick P, Popik P, Trullas R (2009) Glutamate-based antidepres- sants: 20 years on. Trends Pharmacol Sci 30:563–569 Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu GS, Tsien JZ (1999) Genetic enhancement of learning and memory in mice. Nature 401:63–69 Vollenweider FX, Bachle D, Umbricht D, Geyer M, Hell D (1999) Sertindole reduces S-ketamine induced attentional deficits in healthy volunteers. Biol Psychiatry 45:100S Wang D, Cui Z, Zeng Q, Kuang H, Wang LP, Tsien JZ, Cao X (2009) Genetic enhancement of memory and long-term potentiation but not CA1 long-term depression in NR2B transgenic rats. PLoS ONE 4:e7486 Wenzel A, Scheurer L, Kunzi R, Fritschy JM, Mohler H, Benke D (1995) Distribution of NMDA receptor subunit proteins NR2A, 2B, 2C and 2D in rat brain. NeuroReport 7:45–48 Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864 Zhuo JM, Prescott SL, Murray ME, Zhang HY, Baxter MG, Nicolle MM (2007) Early discrimination reversal learning impairment and preserved spatial learning in a longitudinal study of Tg2576 APPsw mice. Neurobiol Aging 28:1248–1257